News | February 27, 2025
Zydus Lifesciences to launch protection against new strain of influenza virus
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
This certification will open new markets for the Kwality Pharma
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
Subscribe To Our Newsletter & Stay Updated
